BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 326 filers reported holding BIO-TECHNE CORP in Q4 2018. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,470,648 | -25.6% | 506,400 | -10.8% | 0.03% | -12.9% |
| Q2 2023 | $46,357,677 | +0.3% | 567,900 | -8.8% | 0.03% | -3.1% |
| Q1 2023 | $46,220,370 | -12.5% | 623,000 | -2.3% | 0.03% | -15.8% |
| Q4 2022 | $52,836,000 | +9.5% | 637,500 | +275.2% | 0.04% | +8.6% |
| Q3 2022 | $48,252,000 | -18.2% | 169,900 | -0.2% | 0.04% | -12.5% |
| Q2 2022 | $58,998,000 | -20.0% | 170,200 | 0.0% | 0.04% | -4.8% |
| Q1 2022 | $73,703,000 | -4.1% | 170,200 | +14.5% | 0.04% | -8.7% |
| Q4 2021 | $76,877,000 | +3.1% | 148,600 | -3.4% | 0.05% | -2.1% |
| Q3 2021 | $74,575,000 | +4.6% | 153,900 | -2.8% | 0.05% | +6.8% |
| Q2 2021 | $71,276,000 | +111.6% | 158,300 | +79.5% | 0.04% | +100.0% |
| Q1 2021 | $33,690,000 | +21.8% | 88,211 | +1.3% | 0.02% | +10.0% |
| Q4 2020 | $27,662,000 | +28.9% | 87,111 | +0.6% | 0.02% | +17.6% |
| Q3 2020 | $21,456,000 | -5.1% | 86,611 | +1.2% | 0.02% | -10.5% |
| Q2 2020 | $22,607,000 | +61.3% | 85,611 | +15.8% | 0.02% | +26.7% |
| Q1 2020 | $14,015,000 | -12.3% | 73,911 | +1.5% | 0.02% | -6.2% |
| Q4 2019 | $15,983,000 | +14.7% | 72,811 | +2.2% | 0.02% | +6.7% |
| Q3 2019 | $13,934,000 | -4.8% | 71,211 | +1.4% | 0.02% | -6.2% |
| Q2 2019 | $14,638,000 | +7.1% | 70,211 | +2.0% | 0.02% | +6.7% |
| Q1 2019 | $13,662,000 | +41.3% | 68,811 | +3.0% | 0.02% | +25.0% |
| Q4 2018 | $9,669,000 | -27.7% | 66,811 | +2.0% | 0.01% | -20.0% |
| Q3 2018 | $13,371,000 | +39.0% | 65,511 | +0.8% | 0.02% | +36.4% |
| Q2 2018 | $9,618,000 | -2.0% | 65,011 | 0.0% | 0.01% | -8.3% |
| Q1 2018 | $9,819,000 | +19.1% | 65,011 | +2.2% | 0.01% | +33.3% |
| Q4 2017 | $8,241,000 | +9.2% | 63,611 | +1.9% | 0.01% | 0.0% |
| Q3 2017 | $7,545,000 | +2.9% | 62,411 | 0.0% | 0.01% | 0.0% |
| Q2 2017 | $7,333,000 | +16.9% | 62,411 | +1.1% | 0.01% | +12.5% |
| Q1 2017 | $6,273,000 | -0.5% | 61,711 | +0.7% | 0.01% | -20.0% |
| Q4 2016 | $6,305,000 | -4.5% | 61,311 | +1.7% | 0.01% | -9.1% |
| Q3 2016 | $6,604,000 | -5.0% | 60,311 | -2.1% | 0.01% | 0.0% |
| Q2 2016 | $6,948,000 | +23.6% | 61,611 | 0.0% | 0.01% | +10.0% |
| Q1 2016 | $5,622,000 | +26.7% | 61,611 | +24.9% | 0.01% | -9.1% |
| Q4 2015 | $4,438,000 | -2.7% | 49,311 | 0.0% | 0.01% | -8.3% |
| Q3 2015 | $4,559,000 | +11.0% | 49,311 | +18.3% | 0.01% | +9.1% |
| Q2 2015 | $4,106,000 | +0.3% | 41,700 | +2.2% | 0.01% | 0.0% |
| Q1 2015 | $4,092,000 | +9.6% | 40,800 | +1.0% | 0.01% | -21.4% |
| Q4 2014 | $3,733,000 | – | 40,400 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $13,206,000 | 5.33% |
| Montanaro Asset Management Ltd | 101,950 | $28,954,000 | 4.43% |
| Jackson Square Partners, LLC | 521,991 | $148,245,000 | 3.89% |
| Sandhill Capital Partners LLC | 119,671 | $33,987,000 | 3.88% |
| STONE RUN CAPITAL, LLC | 22,055 | $6,264,000 | 3.38% |
| Ownership Capital B.V. | 610,466 | $173,372,000 | 3.35% |
| Brown Capital Management | 823,303 | $233,818,000 | 3.28% |
| DF DENT & CO INC | 671,348 | $190,663,000 | 2.94% |
| Westwind Capital | 27,931 | $7,932,000 | 2.78% |
| MAIRS & POWER INC | 673,620 | $191,308,000 | 2.41% |